Last reviewed · How we verify
GSK189075
At a glance
| Generic name | GSK189075 |
|---|---|
| Also known as | ketoconazole, GW869682 |
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM) (PHASE2)
- Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive (PHASE2)
- A Study to Assess the Safety of Single Doses of GSK189075 in Subjects With Type 1 Diabetes Mellitus (PHASE2)
- A Study To Assess The Safety And Tolerability Of GSK189075 When Given With A Total Daily Dose Of >/ 2000mg of Metformin (PHASE1)
- A Study to Assess the Safety of Repeated Doses of GSK189075 and WELLBUTRIN SR in Healthy Male Subjects (PHASE1)
- Investigation Of Weight Loss And Body Composition Changes After Dosing With Either Placebo Or One Of Two Active Drugs (PHASE1)
- GSK189075, GW869682 Or Placebo In Type 2 Diabetic Patients (PHASE2)
- Drug Interactions From Simultaneous Administration Of Metformin And GSK189075 To Subjects With Type 2 Diabetes (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK189075 CI brief — competitive landscape report
- GSK189075 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI